Welcome to our dedicated page for Novabay Pharma news (Ticker: NBY), a resource for investors and traders seeking the latest updates and insights on Novabay Pharma stock.
NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) generates frequent news related to corporate strategy, asset sales, stockholder actions, and exchange listing matters. Historically focused on scientifically created and clinically proven eyecare, wound care, and skin care products, NovaBay’s recent headlines have centered on the Avenova eyecare brand and significant changes to its business structure.
News coverage for NovaBay has included announcements about the completion of the sale of its Avenova eyecare business and related assets to PRN Physician Recommended Nutriceuticals, LLC. The company has reported that this asset sale represented substantially all of its assets and required stockholder approval at special meetings. These developments are important for understanding how NovaBay has monetized its historical operating business and redirected value to stockholders.
Another major category of news involves stockholder meetings and proposals. NovaBay has issued multiple press releases about special meetings and reconvened meetings where stockholders were asked to vote on the sale of the Avenova business and on a Plan of Complete Liquidation and Dissolution. Later communications describe stockholder approval of the Dissolution proposal and the Board’s decision to evaluate alternative strategic options, including mergers, reverse mergers, strategic partnerships, and licensing transactions.
More recent items highlight an investment transaction involving Series D and Series E non-voting convertible preferred stock, the declaration of a one-time special cash dividend, and NovaBay’s disclosure that it regained compliance with NYSE American continued listing standards. Investors following NBY news can track updates on these capital structure changes, special dividend mechanics, and any future post-investment transaction the company may pursue. This news page offers a consolidated view of NovaBay’s press releases and related coverage, providing context on how its strategic direction and corporate actions are evolving over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
NovaBay Pharmaceuticals, a developer of eyecare and skincare products, is introducing its new DERMAdoctor Comfort + Joy Psoriasis Therapeutic Moisturizing Cream featuring 3% Salicylic Acid, aimed at individuals suffering from psoriasis. This product will be showcased on QVC during the program Jane & Shawn’s Beauty Secrets at
NovaBay Pharmaceuticals reported a strong financial performance for the fourth quarter and full year 2022, with net product revenue increasing by 15% in Q4 to $3.6 million, and by 41% year-over-year to $14.4 million. The significant growth was fueled by a 143% surge in wound care revenue and successful digital marketing optimization, leading to lower marketing expenses. However, gross margin for Q4 declined to 48% from 53% due to higher sales of lower margin products, and the company recorded a net loss of $8.2 million in Q4, driven primarily by a $6.7 million non-cash impairment charge related to DERMAdoctor assets.
NovaBay Pharmaceuticals (NYSE American: NBY) plans to report its financial results for the fourth quarter and full year ended December 31, 2022 after market close on March 30, 2023. The company will also hold a conference call for investors at 4:30 p.m. ET on the same day. Participants can pre-register for the call to gain immediate access and avoid live operator delays. The call will also be available via webcast, and a replay will be accessible for two hours post-call until April 20, 2023. NovaBay specializes in developing and selling eyecare and skincare products, including its prominent product, Avenova.
NovaBay Pharmaceuticals (NYSE American: NBY) has announced a partnership with Eyeganics to market Organic Tears, an over-the-counter eye drop solution featuring 0.2% organic glycerin. This product, available on Avenova.com, is USDA-certified as 100% organic and preservative-free, designed specifically for dry eye relief. Each bottle dispenses over 250 drops, offering a cost advantage over single-use vials. CEO Justin Hall emphasized the product enhances Avenova's offerings, while Eyeganics' Dan Friederich highlighted its natural formulation, catering to patients sensitive to chemicals in other drops.
NovaBay Pharmaceuticals (NBY) has launched Avenova Eye Health Support, an OTC oral supplement designed to alleviate dry eye symptoms. This product uniquely combines MaquiBright, an antioxidant-rich extract from maqui berries, with high-quality omega-3 oils. The supplement is available in 60 softgel capsules for
Clinical studies indicate that participants experienced an 89% increase in tear production and a 57% improvement in discomfort after four weeks of use. The global dry eye market is projected to grow at 5% annually, nearing
FAQ
What is the current stock price of Novabay Pharma (NBY)?
What is the market cap of Novabay Pharma (NBY)?
